We conducted an observational retrospective study of all adults hospitalized for documented varicella-zoster virus (VZV) meningitis or encephalitis during years 2000–2015 in one referral centre. Thirty-six patients (21 males, 15 females) were included, with meningitis (n = 21), or meningoencephalitis (n = 15). Median age was 51 years [interquartile range, 35–76], and 6 patients (17%) were immunocompromised. Aciclovir was started in 32 patients (89%), with a median dose of 11 mg/kg/8 h [10–15]. No patient died, but 12 (33%) had neurological sequelae at discharge. Age was the only variable associated with adverse outcome (OR 1.98 [1.17–3.35] per 10-year increment, P = 0.011).

我们对 2000 年至 2015 年期间在一个转诊中心因记录在案的水痘-带状疱疹病毒 (VZV) 脑膜炎或脑炎住院的所有成年人进行了一项观察性回顾性研究。包括 36 名患者（21 名男性，15 名女性），患有脑膜炎 ( n = 21) 或脑膜脑炎 ( n = 15)。中位年龄为 51 岁 [四分位距，35-76]，6 名患者 (17%) 免疫功能低下。32 名患者 (89%) 开始使用阿昔洛韦，中位剂量为 11 mg/kg/8 小时 [10–15]。没有患者死亡，但 12 (33%) 名患者在出院时有神经系统后遗症。年龄是与不良结果相关的唯一变量（OR 1.98 [1.17–3.35] 每 10 年递增，P = 0.011）。